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Discussion:	
During	the	in	vitro	release	studies,	RPV	rings	were	manufactured	and	release	study	was	set	up	
prior	to	the	manufacturing	of	DTG	rings	hence	why	the	study	is	longer	than	DTG’s	study.	The	
total	amount	of	RPV	was	released	after	about	1	year	whereas	DTG’s	release	plateaued.	A	
possible	reason	for	the	plateau	is	the	loss	of	sink	conditions	despite	the	addition	of	1ml	buffer	
following	sampling.	Another	difference	is	due	to	release	profiles	are	drug	specific.	If	compared	
side	by	side	at	day	225,	85%	of	RPV	and	60%	of	DTG	had	been	released	from	the	respected	
IVRs.	Regardless	of	the	differences	seen	in	intro,	the	release	profiles	of	both	IVRs	were	
promising	and	lead	to	in	vivo	testing.	
The	evaluation	of	RPV	and	DTG	containing	IVRs	in	vivo	was	necessary	to	determine	the	stability	
and	release	profile	in	the	mouse	model	over	an	extended	period	of	time.	The	BALB/c	mouse	
model	was	chosen	due	to	the	cost	and	availability.	Pharmacokinetics	is	assumed	to	be	
consistent	throughout	mice	regardless	of	immune	system	function.	Both	had	sustained	release	
of	drug	for	the	whole	28	days.			Concentration	of	drug	was	above	the	IC90	for	both	study	drugs	
in	the	vaginal	lavage	and	vaginal	tissue	for	the	study	in	its	entirety.	Drug	levels	locally	were	high	
enough	to	potentially	protect	against	the	transmission	of	HIV	vaginally.	This	is	promising	for	the	
project	moving	forward	towards	the	use	of	combination	ART	IVRs.		
Future	studies	are	needed	to	evaluate	the	efficacy	of	ART	IVRs	for	the	prevention	of	HIV	
transmission.	Next	steps	include	testing	efficacy	in	humanized	bone	marrow/liver/thymus	(BLT)	
mice.	Mice	in	general	are	incapable	of	contracting	HIV,	therefore	a	specialized	BLT	mouse	
model	is	necessary.	An	issue	with	the	current	protocol	is	the	invasive	procedure	needed	to	
implant	the	IVR.	The	method	involves	an	abdominal	incision	and	vascular	trauma,	which	in	itself	
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causes	an	increased	risk	of	contracting	HIV	when	challenged.	Therefore	an	appropriate	amount	
of	time	must	be	given	for	the	mouse	to	heal,	which	differs	from	how	a	female	would	be	using	
the	product.		
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